

SAMPLE(記入見本)

AFFIX BARCODE LABEL — SIF HERE

SAMPLE INFORMATION FORM ※ 必ず、英語で記入をしてください

Please complete sections bi	EIOW III LIIGIISII.		FH 4 FD		· •
PATIENT INFOR	MATION				
FIRST NAME	Hanako		LAST NAME	Yamad	la
DATE OF BIRTH	31/05/1994		PATIENT GENETIC SEX		e / Male
PHONE NUMBER	090 1234 5678	}	EMAIL	hanak	oyamada3105@gmail.com
ETHNICITY	Japanese		SAMPLE COLLECTION DATE	30/07/	2023
ADDRESS	Nishi-Kanda 1-	-3-6			
CITY	Tokyo, Chiyod	a-ku	101-0065		country <mark>Japan</mark>
ORDERING HEA	LTHCARE PROVI	DER INFORMATION			·
CLINIC NAME	H	Hiro Clinic / HUMEDIT	CLINIC ID		
REFERRING HEALTH	CARE PROVIDER	HUMEDIT	'		
PHONE NUMBER			FAX		
EMAIL	info-hi@humedi	t.co.jp	·		
ADDRESS					
CITY		POS	STCODE		COUNTRY Japan
PARTNER TESTI	NC				
		DVENTIA TEST AS WELL?			
YES	CINEKTIAVING ITIE AL	FIRST AND LAST N	NAME: Haru Yamada		DATE OF BIRTH:
□ NO		THOTAINDEAST	Will. Hard Farrada		30/07/2023
COMMENTS:					
REQUESTED TES	ST e below. Please select one.				
FOCUS PANELS					
A-Thalassemia HBA1, HBA2		B-Haemoglobinopa	_	Cystic Fi	brosis
TIDAI, TIDAZ		(Beta-Thalassemia, Si	ckle-Cell Disease) HBB	CFIR	
Duchenne Muscular Becker Muscular DMD		Fragile X Syndrome		Spinal M SMN1, SN	uscular Atrophy 1N2
CORE PANEL					
CFTR • Duchenne GALT • Gaucher D • Non-Syndromic	Muscular Dystrophy; X-li isease; GBA • Medium Cl Hearing Loss GJB2-Relat	nked, DMD • Familial Dysautonomia; E hain Acyl-CoA Dehydrogenase Deficie	ELP1 • Fanconi Anemia, Type C; FANG ncy; ACADM • Mucolipidosis Type N Phenylalaline Hydroxylase Deficiend	CC • Fragile X V; MCOLN1 •	• Canavan Disease; ASPA • Cystic Fibrosis; Syndrome; X-linked, FMR1 • Galactosemia; Niemann-Pick Disease, Types A/B; SMPD1 onurea); PAH • Sickle-Cell Disease; HBB •
COMPREHENSIVE PA	ANEL				
231 genes Includes all genes	of the Core panel. For the	e complete list of genes tested, please	visit www.medicover-genetics.com		
TEST INDICATION)NS				
PREGNANCY TEST	- 「ING※女性の場合のみ	チェック FAMILY HISTORY (P	lease specify):		
CONSANGUINITY		HIGH RISK ETHNIC	ттү	CARRIER	PARTNER
EGG/SPERM DON	OR	OTHER (Please speci	ify):	_	
COMMENTS:					
FOR LABORATORY	USE ONLY	ORDER NUMBER	LAB ID NUMBER		KIT LOT NUMBER
COMMENTS			DATE & TIME OF RECEIPT (DD/MM/YY	НН:ММ)	RECEIVED BY















PATIENT CONSENT

By placing my signature below I hereby:

- 1. Confirm that I have read, or have had read to me, the attached Patient Informed Consent and that I understand it.
- 2. Declare that I have had the opportunity to receive counselling from my referring healthcare provider on the Adventia test and to discuss with the healthcare provider all aspects of the Adventia test and this form including the benefits, risks and limitations of the Adventia test, as well as the reasons for performing the test and availability of alternative testing options to my satisfaction.
- 3. Authorize my referring healthcare provider to collect the necessary biological sample, and to submit this form and transport the samples to Medicover Genetics laboratories for the purposes of conducting the tests requested with this form.
- 4. Authorize Medicover Genetics to use part or the entirety of the biological sample for the purposes of conducting the tests requested with this form.
- 5. Authorize Medicover Genetics to communicate the results of the test to my referring healthcare provider.
- 6. Confirm that all the information on this form is true to the best of my knowledge.

Your test results and any unused biological material can help Medicover Genetics improve and further develop the quality, accuracy and effectiveness of diagnosis and help us expand the scope of genetic testing. For this reason, Medicover Genetics would like to use your anonymized, de-identified (i.e. after removing all the personal information from which you can be identified) test results and unused biological material.

For the above scope, I consent to the inclusion of my test results in Medicover Genetics' database, the coding, storing and using of biological material.

PATIENT/GUARDIAN SIGNATURE

DATE

Hanako Yamada

30/07/2023

HEALTHCARE PROVIDER ATTESTATION

I hereby certify and undertake that:

- 1. I am the referring healthcare professional ordering this test.
- 2. The test results will determine my patient's medical management and treatment options.
- 3. The patient has been informed about the nature and purpose of the testing.
- 4. The patient has been duly and thoroughly counseled about the test and has received all the advice necessary to provide their informed consent, including the benefits, risks, and limitations of the Adventia test.
- 5. I have answered all the patient's queries about the Adventia test.

Neas Engomis 31, Nicosia, 2409 Cyprus

Phone: +357 22266888 Fax: +357 22266899

- 6. This form has been completed according to the wishes and instructions of the patients.
- 7. I have obtained the patient's informed consent and have attested their signature.

LIEVITI	ICADE DDC	OVIDER SIG	NIATLIDE
HEALIE	1CARE PRU	JVIDEK SIG	NATURE

DATE













F-OPR-01/06-V7-EN